Home/Filings/4/0000950170-25-035537
4//SEC Filing

Fox Christine 4

Accession 0000950170-25-035537

CIK 0000818686other

Filed

Mar 6, 7:00 PM ET

Accepted

Mar 7, 4:25 PM ET

Size

5.9 KB

Accession

0000950170-25-035537

Insider Transaction Report

Form 4
Period: 2025-03-05
Fox Christine
EVP, Head of U.S. Commercial
Transactions
  • Award

    Restricted Share Units

    2025-03-05+71,27871,278 total
    Ordinary Shares (71,278 underlying)
Footnotes (3)
  • [F1]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  • [F2]Restricted share units were granted on March 5, 2025, with 17,819 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 17,821 vesting on March 5, 2029.
  • [F3]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Documents

1 file

Issuer

TEVA PHARMACEUTICAL INDUSTRIES LTD

CIK 0000818686

Entity typeother

Related Parties

1
  • filerCIK 0001998173

Filing Metadata

Form type
4
Filed
Mar 6, 7:00 PM ET
Accepted
Mar 7, 4:25 PM ET
Size
5.9 KB